Fenclozic acid

Fenclozic acid is a nonsteroidal anti-inflammatory drug (NSAID) that was developed in the 1960s by Boots UK. It was withdrawn from the market due to its association with hepatotoxicity.

History

Fenclozic acid was developed by Boots UK, a British health and beauty retailer and pharmacy chain, in the 1960s. It was one of the many nonsteroidal anti-inflammatory drugs (NSAIDs) developed during this period. However, it was withdrawn from the market due to concerns about its safety, specifically its potential to cause hepatotoxicity.

Pharmacology

As a nonsteroidal anti-inflammatory drug, fenclozic acid works by inhibiting the production of prostaglandins, chemicals in the body that cause inflammation and pain. It does this by blocking the action of the enzyme cyclooxygenase, which is responsible for the production of prostaglandins.

Side effects

The main concern with fenclozic acid is its potential to cause hepatotoxicity, or liver damage. This was the reason for its withdrawal from the market. Other side effects may include gastrointestinal issues, such as stomach pain, nausea, and diarrhea, which are common side effects of NSAIDs.

Current status

Despite its withdrawal from the market, fenclozic acid is still used in scientific research, particularly in studies investigating the mechanisms of drug-induced liver injury.

See also

• Nonsteroidal anti-inflammatory drug
• Hepatotoxicity
• Boots UK

‎